206 related articles for article (PubMed ID: 12099575)
1. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.
Gleave ME; Zellweger T; Chi K; Miyake H; Kiyama S; July L; Leung S
Invest New Drugs; 2002 May; 20(2):145-58. PubMed ID: 12099575
[TBL] [Abstract][Full Text] [Related]
2. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
[TBL] [Abstract][Full Text] [Related]
3. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
Gleave M; Miyake H
World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
[TBL] [Abstract][Full Text] [Related]
4. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer.
Gleave M; Nelson C; Chi K
Curr Drug Targets; 2003 Apr; 4(3):209-21. PubMed ID: 12643471
[TBL] [Abstract][Full Text] [Related]
5. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
[TBL] [Abstract][Full Text] [Related]
6. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy.
July LV; Akbari M; Zellweger T; Jones EC; Goldenberg SL; Gleave ME
Prostate; 2002 Feb; 50(3):179-88. PubMed ID: 11813210
[TBL] [Abstract][Full Text] [Related]
7. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
[TBL] [Abstract][Full Text] [Related]
8. Antisense therapy: current status in prostate cancer and other malignancies.
Gleave M; Miyake H; Zangemeister-Wittke U; Jansen B
Cancer Metastasis Rev; 2002; 21(1):79-92. PubMed ID: 12400997
[TBL] [Abstract][Full Text] [Related]
9. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
Miyake H; Hara I; Kamidono S; Gleave ME; Eto H
Oncol Rep; 2003; 10(2):469-73. PubMed ID: 12579291
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
[TBL] [Abstract][Full Text] [Related]
12. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer.
Gleave M; Miyake H; Chi K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():47-57. PubMed ID: 16273354
[TBL] [Abstract][Full Text] [Related]
13. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
14. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
15. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2009; 26(2):124-30. PubMed ID: 18686047
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
Miayake H; Tolcher A; Gleave ME
J Natl Cancer Inst; 2000 Jan; 92(1):34-41. PubMed ID: 10620631
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model.
Yamanaka K; Gleave ME; Hara I; Muramaki M; Miyake H
Mol Cancer Ther; 2005 Feb; 4(2):187-95. PubMed ID: 15713890
[TBL] [Abstract][Full Text] [Related]
18. Clusterin and IGFBPs as antisense targets in prostate cancer.
Gleave M; Jansen B
Ann N Y Acad Sci; 2003 Dec; 1002():95-104. PubMed ID: 14751827
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity.
Miyake H; Hara I; Kamidono S; Gleave ME
Int J Urol; 2001 Jul; 8(7):337-49. PubMed ID: 11442654
[TBL] [Abstract][Full Text] [Related]
20. Androgens and prostate cancer.
So AI; Hurtado-Coll A; Gleave ME
World J Urol; 2003 Nov; 21(5):325-37. PubMed ID: 14586548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
